Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia.
Saved in:
| Title: | Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia. |
|---|---|
| Authors: | Bhatnagar B; Division of Hematology and Medical Oncology, West Virginia University Cancer Institute, Wheeling Hospital, Wheeling, WV, USA., Zhao Q; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Columbus, USA., Mims AS; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Columbus, USA., Vasu S; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Columbus, USA., Behbehani GK; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Columbus, USA., Larkin K; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Columbus, USA., Blachly JS; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Columbus, USA., Badawi MA; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University., Hill KL; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University., Dzwigalski KR; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University., Phelps MA; The Ohio State University Comprehensive Cancer Center, Columbus, USA.; Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University., Blum W; Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA., Klisovic RB; Department of Hematology and Medical Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA., Ruppert AS; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Columbus, USA., Ranganathan P; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.; The Ohio State University Comprehensive Cancer Center, Columbus, USA., Walker AR; Moffitt Cancer Center, University of South Florida, Tampa, FL, USA., Garzon R; Huntsman Cancer Institute, University of Utah, Salt Lake City UT, USA. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2023 Dec; Vol. 64 (13), pp. 2091-2100. Date of Electronic Publication: 2023 Sep 04. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1029-2403 |
|---|---|
| DOI: | 10.1080/10428194.2023.2253480 |
